NATCO Pharma Limited

Equities

NATCOPHARM

INE987B01026

Pharmaceuticals

Market Closed - NSE India S.E. 08:02:00 2024-03-28 am EDT 5-day change 1st Jan Change
952 INR -2.20% Intraday chart for NATCO Pharma Limited +0.21% +17.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
INDIA STOCKS-Indian shares erase early gains, weighed down by IT stocks RE
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024 CI
Transcript : NATCO Pharma Limited, Q3 2024 Earnings Call, Feb 15, 2024
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024 CI
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Cellogen Therapeutics announced that it has received $2 million in funding from NATCO Pharma Limited CI
Floods Disrupt Operations of Natco Pharma's Plant in Tamil Nadu, India MT
Transcript : NATCO Pharma Limited, Q2 2024 Earnings Call, Nov 15, 2023
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend MT
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023 CI
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India MT
Transcript : NATCO Pharma Limited - Shareholder/Analyst Call
Redcliffe Hygiene Private Limited announced that it expects to receive INR 500 million in funding from Rainmatter, Alkemi Growth Capital LLP, NATCO Pharma Limited CI
Indian Equities End Higher for Sixth Straight Day, Buoyed by Banking, Public Sector Enterprises MT
Natco Pharma, Three Others Face Antitrust Violation Raps in US; Natco Pharma Shares Drop 3% MT
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit RE
Indian shares set to open flat on caution ahead of GDP data RE
Transcript : NATCO Pharma Limited, Q1 2024 Earnings Call, Aug 10, 2023
Natco Pharma to Form UK Arm MT
NATCO Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24 CI
Natco Pharma Seeks US FDA Approval for Bladder Cancer Drug MT
23,861,140 Equity Shares of MedPlus Health Services Limited are subject to a Lock-Up Agreement Ending on 20-JUN-2023. CI
Natco Pharma Gets US FDA's Final Approval for Generic Colorectal Cancer Drug MT
Chart NATCO Pharma Limited
More charts
Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The Company operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
952 INR
Average target price
930.8 INR
Spread / Average Target
-2.23%
Consensus
  1. Stock
  2. Equities
  3. Stock NATCO Pharma Limited - NSE India S.E.
  4. News NATCO Pharma Limited
  5. Natco Pharma : Seals Licensing Deal for COVID-19 Treatment Drug